Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing four investigational medicines in clinical development, along with multiple research programs. Source
No articles found.
Amgen is committed to unlocking the potential of biology for patients suffering fr...
Amgen is committed to unlocking the potential o...
 
                  Revolutionizing the Approach to Spine Surgery We are more than a medical technolo...
Revolutionizing the Approach to Spine Surgery ...
 
                  Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
 
                  Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
 
                  We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
 
                  Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
 
                  Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
Join the National Investor Network and get the latest information with your interests in mind.